Literature DB >> 22689326

Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: implications for future impact on prevention.

Anneke Steens1, Cornelia C H Wielders, Johannes A Bogaards, Hendriek C Boshuizen, Sabine C de Greeff, Hester E de Melker.   

Abstract

Several countries recently added human papillomavirus (HPV) vaccination to cervical cancer screening in the effort to prevent cervical cancer. They include the Netherlands, where both programs are free. To estimate their combined future impact on cancer prevention, information is needed on the association between participation in vaccination now and in screening in the future and on what groups are at risk for nonparticipation. We studied the association between participation in screening by mothers and in vaccination by their daughters. Girls' vaccination status was matched by house-address with their mothers' screening participation. We estimated the effect on cancer incidence by means of computer simulation. We investigated risk groups for nonparticipation using multivariable multilevel logistic regression and calculated population-attributable fractions. Our results, based on 89% of girls invited for vaccination in 2009 (n = 337,368), show that vaccination status was significantly associated with mothers' screening participation (odds ratio: 1.54 [95% confidence interval: 1.51-1.57]). If a mother's screening is taken as proxy of a girl's future screening, only 13% of the girls will not participate in either program compared to 23% if screening alone is available. The positive association between vaccination and screening resulted in slightly lower model estimates of the impact of vaccination on cancer incidence, compared to estimates assuming no association. Girls with nonwestern ethnicities, with young mothers, who live in urban areas with low socioeconomic status, are at risk for nonparticipation. A significant part of potential nonscreeners may be reached through HPV vaccination. Estimates made before vaccination was introduced only slightly overestimated its impact on cervical cancer incidence.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689326     DOI: 10.1002/ijc.27671

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

Review 1.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071

2.  Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years.

Authors:  Ellinor Östensson; Susanna Alder; K Miriam Elfström; Karin Sundström; Niklas Zethraeus; Marc Arbyn; Sonia Andersson
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

3.  Association between human papillomavirus vaccine status and other cervical cancer risk factors.

Authors:  Harriet L Bowyer; Rachael H Dodd; Laura A V Marlow; Jo Waller
Journal:  Vaccine       Date:  2014-06-17       Impact factor: 3.641

4.  Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands.

Authors:  Madelief Mollers; Karin Lubbers; Symen K Spoelstra; Willibrord C M Weijmar-Schultz; Toos Daemen; Tjalke A Westra; Marianne A B van der Sande; Hans W Nijman; Hester E de Melker; Adriana Tami
Journal:  BMC Public Health       Date:  2014-03-28       Impact factor: 3.295

5.  Association between mothers' screening uptake and daughters' HPV vaccination: a quasi-experimental study on the effect of an active invitation campaign.

Authors:  Francesco Venturelli; Flavia Baldacchini; Cinzia Campari; Cinzia Perilli; Maria Grazia Pascucci; Alba Carola Finarelli; Luigi Moscara; Paolo Giorgi Rossi
Journal:  BMJ Open       Date:  2017-09-25       Impact factor: 2.692

6.  Turkish and Moroccan Dutch women's views of using a self-sampling kit for human papillomavirus testing as a tool for cervical cancer screening: What are the barriers and the motivators?

Authors:  Femke Hilverda; Katleen Fissers; Thijs van den Broek
Journal:  Womens Health (Lond)       Date:  2021 Jan-Dec

Review 7.  Determinants in the Uptake of the Human Papillomavirus Vaccine: A Systematic Review Based on European Studies.

Authors:  Victoria Fernández de Casadevante; Julita Gil Cuesta; Lourdes Cantarero-Arévalo
Journal:  Front Oncol       Date:  2015-06-24       Impact factor: 6.244

Review 8.  The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs.

Authors:  Paolo Giorgi Rossi; Flavia Baldacchini; Guglielmo Ronco
Journal:  Front Oncol       Date:  2014-02-10       Impact factor: 6.244

9.  Current views and advances on Paediatric Virology: An update for paediatric trainees.

Authors:  Ioannis N Mammas; Anne Greenough; Maria Theodoridou; Anna Kramvis; Iliana Christaki; Chryssie Koutsaftiki; Maria Koutsaki; Dimitra M Portaliou; Georgia Kostagianni; Paraskevi Panagopoulou; George Sourvinos; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2015-11-24       Impact factor: 2.447

10.  Ethnic background and human papillomavirus vaccine uptake in Denmark: A countrywide retrospective cohort study including 274,154 women aged 19-28 years.

Authors:  Victoria Fernández de Casadevante; Lourdes Cantarero-Arévalo; Julita Gil Cuesta; Palle Valentiner-Branth
Journal:  Papillomavirus Res       Date:  2016-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.